BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND TAL1, TCL5, 6886, ENSG00000162367, SCL, P17542, tal-1 AND Treatment
58 results:

  • 1. Suppression of super-enhancer-driven tal1 expression by KLF4 in T-cell acute lymphoblastic leukemia.
    Noura M; Matsuo H; Yasuda T; Tsuzuki S; Kiyoi H; Hayakawa F
    Oncogene; 2024 Feb; 43(6):447-456. PubMed ID: 38102337
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Inhibition of the NOTCH and mTOR pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia.
    Chang YS; Gills JJ; Kawabata S; Onozawa M; Della Gatta G; Ferrando AA; Aplan PD; Dennis PA
    Int J Oncol; 2023 Nov; 63(5):. PubMed ID: 37800623
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. The Clinicogenomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia.
    O'Connor D; Demeulemeester J; Conde L; Kirkwood A; Fung K; Papaleonidopoulou F; Bloye G; Farah N; Rahman S; Hancock J; Bateman C; Inglott S; Mee J; Herrero J; Van Loo P; Moorman AV; Vora A; Mansour MR
    J Clin Oncol; 2023 Jul; 41(19):3545-3556. PubMed ID: 37098241
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Harnessing the MYB-dependent tal1 5'super-enhancer for targeted therapy in T-ALL.
    Smith C; Touzart A; Simonin M; Tran-Quang C; Hypolite G; Latiri M; Andrieu GP; Balducci E; Dourthe MÉ; Goyal A; Huguet F; Petit A; Ifrah N; Baruchel A; Dombret H; Macintyre E; Plass C; Ghysdael J; Boissel N; Asnafi V
    Mol Cancer; 2023 Jan; 22(1):12. PubMed ID: 36650499
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. [Characteristics and prognostic effects of NOTCH1/FBXW7 gene mutations in T-cell acute lymphoblastic leukemia patients].
    Wu CY; Li YL; Dong XY; Yang SW; Shang BJ; Zhang L; Cheng W; Zhang L; Zhu ZM
    Zhonghua Yi Xue Za Zhi; 2022 Jul; 102(25):1910-1917. PubMed ID: 35768390
    [No Abstract]    [Full Text] [Related]  

  • 6. Prognostic utility of key copy number alterations in T cell acute lymphoblastic leukemia.
    Kumari S; Ali MS; Singh J; Arora M; Verma D; Pandey AK; Benjamin M; Bakhshi S; Palanichamy JK; Sharma A; Singh I; Tanwar P; Singh AR; Pushpam D; Qamar I; Chopra A
    Hematol Oncol; 2022 Oct; 40(4):577-587. PubMed ID: 35644022
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial.
    Zhang Y; Wang Y; Liu Y; Tong C; Wang C; Guo Y; Ti D; Yang Q; Qiao S; Wu Z; Han W
    Leukemia; 2022 Jan; 36(1):189-196. PubMed ID: 34272481
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup.
    Touzart A; Mayakonda A; Smith C; Hey J; Toth R; Cieslak A; Andrieu GP; Tran Quang C; Latiri M; Ghysdael J; Spicuglia S; Dombret H; Ifrah N; Macintyre E; Lutsik P; Boissel N; Plass C; Asnafi V
    Sci Transl Med; 2021 May; 13(595):. PubMed ID: 34039737
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. MiR-7 Functions as a Tumor Suppressor by Targeting the Oncogenes tal1 in T-Cell Acute Lymphoblastic Leukemia.
    Sun H; Zhang Z; Luo W; Liu J; Lou Y; Xia S
    Technol Cancer Res Treat; 2020; 19():1533033820934130. PubMed ID: 32633635
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. [Outcome of children with T cell acute lymphoblastic leukemia treated with Chinese Children Leukemia Group acute lymphoblastic leukemia (CCLG-ALL) 2008 protocol].
    Liu XM; Chen XJ; Zou Y; Wang SC; Wang M; Zhang L; Chen YM; Yang WY; Guo Y; Zhu XF
    Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):761-766. PubMed ID: 31594062
    [No Abstract]    [Full Text] [Related]  

  • 11. Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors.
    Gunaratne PH; Pan Y; Rao AK; Lin C; Hernandez-Herrera A; Liang K; Rait AS; Venkatanarayan A; Benham AL; Rubab F; Kim SS; Rajapakshe K; Chan CK; Mangala LS; Lopez-Berestein G; Sood AK; Rowat AC; Coarfa C; Pirollo KF; Flores ER; Chang EH
    Cancer; 2019 Jul; 125(14):2409-2422. PubMed ID: 31012964
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Eradication of Central Nervous System Leukemia of T-Cell Origin with a Brain-Permeable LSD1 Inhibitor.
    Saito S; Kikuchi J; Koyama D; Sato S; Koyama H; Osada N; Kuroda Y; Akahane K; Inukai T; Umehara T; Furukawa Y
    Clin Cancer Res; 2019 Mar; 25(5):1601-1611. PubMed ID: 30518632
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. [Study on Immunophenotypes and Gene of Acute Lymphoblastic Leukemia].
    Zhao XF; Wang HY; Zhao X; Cheng HC; Li W; Liu SW; Qiu L; Ma J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):947-952. PubMed ID: 30111389
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. [Genetic basis of pediatric T-cell acute lymphoblastic leukemia and its clinical impact].
    Takita J
    Rinsho Ketsueki; 2018; 59(7):953-959. PubMed ID: 30078808
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-κB.
    Cordas Dos Santos DM; Eilers J; Sosa Vizcaino A; Orlova E; Zimmermann M; Stanulla M; Schrappe M; Börner K; Grimm D; Muckenthaler MU; Kulozik AE; Kunz JB
    BMC Cancer; 2018 Jun; 18(1):663. PubMed ID: 29914415
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. ECPIRM, a Potential Therapeutic Agent for Cutaneous T-Cell lymphoma, Inhibits Cell Proliferation and Promotes Apoptosis via a JAK/STAT Pathway.
    Yang H; Ma P; Cao Y; Zhang M; Li L; Wei J; Tao L; Qian K
    Anticancer Agents Med Chem; 2018; 18(3):401-411. PubMed ID: 28356009
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. [A clinical analysis of 10 cases with cardiac lymphoma].
    Li YH; Shi CY; Duan FQ; Pang Y; Li HB; Zhang LQ; Liu ZH; Ouyang L; Yue CY; Xie MC; Jiang ZJ; Xiao Y
    Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):102-106. PubMed ID: 28279032
    [No Abstract]    [Full Text] [Related]  

  • 18. Neither 10- nor 14-Day Sequential treatment is better than Standard Triple Therapy for Helicobacter Pylori Eradication.
    Warrington E; López-Román O; Tirado Montijo R; Urbina R; Cruz-Correa M; Toro DH
    P R Health Sci J; 2016 Dec; 35(4):203-208. PubMed ID: 27898166
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. [Clinical Characteristics and treatment Efficacy of Children with SIL/tal1 Positive T-Cell Acute Lymphoblastic Leukemia].
    Liu X; Li WJ; Zhao XX; Gao C; Zhao W; Jiang J; Zhang RD; Xie J; Shi HW; Wang B; Zhang YH; Ma XL; Zhou X; Wu MY; Cui L; Li ZG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):681-6. PubMed ID: 27342490
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Immunophenotyping with CD135 and CD117 predicts the FLT3, IL-7R and TLX3 gene mutations in childhood T-cell acute leukemia.
    Noronha EP; Andrade FG; Zampier C; de Andrade CF; Terra-Granado E; Pombo-de-Oliveira MS;
    Blood Cells Mol Dis; 2016 Mar; 57():74-80. PubMed ID: 26852660
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.